XExploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design

Research output: Contribution to journalArticle

Abstract

HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate several sources of outcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the clinic and to develop the next generation of PrEP candidates.

Original languageEnglish (US)
JournalCell
Volume155
Issue number3
DOIs
StatePublished - Oct 24 2013

Fingerprint

Clinical Trials
HIV
Pharmacology
Pharmaceutical Preparations
Pre-Exposure Prophylaxis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

XExploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. / Hendrix, Craig.

In: Cell, Vol. 155, No. 3, 24.10.2013.

Research output: Contribution to journalArticle

@article{96c0c737c2284d4199f9abb0984cba18,
title = "XExploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design",
abstract = "HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate several sources of outcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the clinic and to develop the next generation of PrEP candidates.",
author = "Craig Hendrix",
year = "2013",
month = "10",
day = "24",
doi = "10.1016/j.cell.2013.09.030",
language = "English (US)",
volume = "155",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - XExploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design

AU - Hendrix, Craig

PY - 2013/10/24

Y1 - 2013/10/24

N2 - HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate several sources of outcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the clinic and to develop the next generation of PrEP candidates.

AB - HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate several sources of outcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the clinic and to develop the next generation of PrEP candidates.

UR - http://www.scopus.com/inward/record.url?scp=84886804053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886804053&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2013.09.030

DO - 10.1016/j.cell.2013.09.030

M3 - Article

C2 - 24243011

AN - SCOPUS:84886804053

VL - 155

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -